For accurate detection of all types of genetic aberrations, various technologies are required. By combining information from multiple technologies, researchers can analyse complex samples and get the most complete overview of disease-driving mutations.
OGT offers an integrated portfolio of products providing clinical researchers with the most advanced tools available to study hematological disorders, including CytoCell® fluorescence in-situ hybridization (FISH) probes and myProbes® custom FISH probes, SureSeq™ next generation sequencing (NGS) panels and myPanel™ custom panels, and CytoSure® array products and custom arrays.
Our products are backed by deep technical expertise and dedicated customer support.
Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (above) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.
View ProductMyeloid malignancies are a heterogeneous group of diseases, associated with a wide range of variants ranging from mutations to structural variations. The panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, and is able to detect low-frequency SNVs and indels with confidence. The figure (above) shows a PTD detection spanning exons 2-8 of the KMT2A gene.
View ProductThe PML probe mix, labeled in red, consists of a 151kb probe centromeric to the PML gene and a 174kb probe telomeric to the PML gene.
View ProductThe RARα (RARA) probe mix, labelled in green, consists of a 167kb probe centromeric to the RARA gene, including the CASC3 gene, and a 164kb probe, including the telomeric end of the RARα gene as well as the TOP2A and IGFBP4 genes.
View ProductOGT’s range of CytoSure® Cancer +SNP arrays combine long-oligo probes for superior copy number variant (CNV) detection alongside single nucleotide polymorphism (SNP) probes – which function using OGT proprietary technology – for accurate identification of loss-of-heterozygosity (LOH). The figure (above) shows a schematic of OGT’s unique SNP probe technology, allowing the use of any reference sample with no restriction digest.
View ProductBenefit from OGT’s extensive array design expertise to produce an array matching your precise specifications. These arrays are ideal if you want to know the precise coordinates of an aberration by analyzing specific areas of the genome at high resolution. The figure (above) shows how our custom arrays can be designed in a variety of formats depending on your desired level of focus, with 1, 2, 4, or 8 arrays available per slide to provide the most cost-effective solution for your research.
View Product